CBC and CBD are both non-psychoactive cannabinoids found in the cannabis plant, each with unique properties and potential therapeutic benefits. CBC interacts primarily with the TRPV1 and TRPA1 receptors, which affect pain perception and inflammation. 

In contrast, CBD has a broader mechanism of action. It interacts with several receptor systems, including the 5-HT1A serotonin receptor, which contributes to its anxiolytic (anxiety-reducing) effects, and the GPR55 receptor, which may regulate blood pressure and bone density. 

CBD is well-known for its anti-inflammatory, analgesic, and antiepileptic properties. It also modulates the endocannabinoid system by inhibiting the enzyme FAAH, which breaks down anandamide, thereby increasing its levels and enhancing its mood-stabilizing effects .

Cannabichromene acid (CBCA) is the precursor to cannabichromene (CBC) in the cannabis plant. CBCA, along with other cannabinoid acids, such as THCA and CBDA, is synthesized in the plant through the enzymatic conversion of cannabigerolic acid (CBGA). Upon exposure to heat or light, CBCA undergoes decarboxylation, losing a carboxyl group to become CBC. This process of decarboxylation transforms the non-psychoactive cannabinoid acids into their active forms, allowing them to interact more effectively with the body's endocannabinoid system (ECS).

CBCA itself has not been as extensively studied as CBC. However, early research suggests that CBCA has rapid and potent antibacterial properties against Staphylococcus aureus (MRSA), similar to CBC.  

‍

7-hydroxymitragynine is like morphine in that it acts as an opioid receptor agonist, explicitly targeting the mu-opioid receptors in the brain. Both substances can produce analgesic (pain-relieving) effects and may induce euphoria or sedation. However, 7-hydroxymitragynine is structurally different and is derived from the kratom plant, whereas morphine is a naturally occurring opiate derived from the opium poppy plant. Additionally, 7-hydroxymitragynine is generally considered to be more potent than morphine in terms of its effects on opioid receptors, although potentially less addictive. 

‍

The percentage of 7-hydroxymitragynine (7-OH mitragynine) in kratom can vary widely depending on the specific strain and preparation method. Generally, 7-OH mitragynine constitutes a small percentage of kratom’s total alkaloid content, typically around 0.01% to 0.04%. However, 7-OH mitragynine extracts can contain a significantly higher ratio. 

One study found that alkaloid-rich fractions, ethanolic extracts, lyophilized teas, and commercial kratom products contained up to 2.8% 7-OH. Another study found concentrations as high as 500% more 7-OH than the average kratom plant. 

‍

‍

High Amanita muscaria doses can result in intense psychoactive effects, such as vivid dreams and hallucinations. Consuming too high a dose for a person’s tolerance level could also cause some adverse effects, such as:

• Dizziness
• Confusion
• Tiredness
• Increased sensitivity to visual and auditory stimuli

‍

Body weight affects a person’s metabolism and tolerance level. Generally, people with higher body weight may require larger Amanita doses to achieve the same effects as those with lower body weight. This variation occurs because a larger body mass can dilute the concentration of the substance.